These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 7488333)

  • 41. Lack of effect of oral N-acetylcysteine on the acute dialysis-related lowering of total plasma homocysteine in hemodialysis patients.
    Bostom AG; Shemin D; Yoburn D; Fisher DH; Nadeau MR; Selhub J
    Atherosclerosis; 1996 Feb; 120(1-2):241-4. PubMed ID: 8645365
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Diet-induced hyperhomocysteinemia impairs vasodilation in 5/6-nephrectomized rats.
    Li L; Hasegawa H; Inaba N; Yoshioka W; Chang D; Liu J; Ichida K
    Amino Acids; 2018 Oct; 50(10):1485-1494. PubMed ID: 30062489
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Homocysteine stimulates monocyte chemoattractant protein-1 expression in the kidney via nuclear factor-kappaB activation.
    Hwang SY; Woo CW; Au-Yeung KK; Siow YL; Zhu TY; O K
    Am J Physiol Renal Physiol; 2008 Jan; 294(1):F236-44. PubMed ID: 17977907
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Plasma sulfate concentration and hyperhomocysteinemia in hemodialysis patients.
    Brunetti M; Terracina L; Timio M; Saronio P; Capodicasa E
    J Nephrol; 2001; 14(1):27-31. PubMed ID: 11281340
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effect of homocysteine lowering on mortality and vascular disease in advanced chronic kidney disease and end-stage renal disease: a randomized controlled trial.
    Jamison RL; Hartigan P; Kaufman JS; Goldfarb DS; Warren SR; Guarino PD; Gaziano JM;
    JAMA; 2007 Sep; 298(10):1163-70. PubMed ID: 17848650
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Glutamate transport regulation of renal glutaminase flux in vivo.
    Carter P; Welbourne T
    Am J Physiol; 1997 Sep; 273(3 Pt 1):E521-7. PubMed ID: 9316441
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Hyperhomocysteinemia as a vascular risk factor in chronic hemodialysis patients].
    Trimarchi H; Young P; Díaz ML; Schropp J; Forrester M; Freixas E
    Medicina (B Aires); 2005; 65(6):513-7. PubMed ID: 16433478
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Hyperhomocysteinemia confers an independent increased risk of atherosclerosis in end-stage renal disease and is closely linked to plasma folate and pyridoxine concentrations.
    Robinson K; Gupta A; Dennis V; Arheart K; Chaudhary D; Green R; Vigo P; Mayer EL; Selhub J; Kutner M; Jacobsen DW
    Circulation; 1996 Dec; 94(11):2743-8. PubMed ID: 8941098
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Homocysteine-lowering vitamin B treatment decreases cardiovascular events in hemodialysis patients.
    Righetti M; Serbelloni P; Milani S; Ferrario G
    Blood Purif; 2006; 24(4):379-86. PubMed ID: 16755160
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Interrelations between plasma homocysteine and intracellular S-adenosylhomocysteine.
    Fu W; Dudman NP; Perry MA; Young K; Wang XL
    Biochem Biophys Res Commun; 2000 Apr; 271(1):47-53. PubMed ID: 10777679
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Folic acid attenuates hyperhomocysteinemia-induced glomerular damage in rats.
    Cao L; Lou X; Zou Z; Mou N; Wu W; Huang X; Tan H
    Microvasc Res; 2013 Sep; 89():146-52. PubMed ID: 23859838
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Association between serum homocysteine and markers of impaired kidney function in adults in the United States.
    Francis ME; Eggers PW; Hostetter TH; Briggs JP
    Kidney Int; 2004 Jul; 66(1):303-12. PubMed ID: 15200438
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Homocysteinemia and vascular disease in end-stage renal disease.
    Dennis VW; Robinson K
    Kidney Int Suppl; 1996 Dec; 57():S11-7. PubMed ID: 8941916
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Hyperhomocysteinemia, diabetes mellitus, and carotid atherosclerosis independently increase atherosclerotic vascular disease outcome in Japanese patients with end-stage renal disease.
    Haraki T; Takegoshi T; Kitoh C; Kajinami K; Wakasugi T; Hirai J; Shimada T; Kawashiri M; Inazu A; Koizumi J; Mabuchi H
    Clin Nephrol; 2001 Aug; 56(2):132-9. PubMed ID: 11522090
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Reduction of plasma homocysteine by folic acid in children with chronic renal failure.
    Kang HG; Lee BS; Hahn H; Lee JH; Ha IS; Cheong HI; Choi Y
    Pediatr Nephrol; 2002 Jul; 17(7):511-4. PubMed ID: 12172764
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Plasma total homocysteine concentration in nephrotic patients with idiopathic membranous nephropathy.
    Arnadottir M; Hultberg B; Berg AL
    Nephrol Dial Transplant; 2001 Jan; 16(1):45-7. PubMed ID: 11208992
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [The treatment of hyperhomocysteinemia in patients on dialysis: folic acid or the high-flow polysulphonic membrane?].
    Lovcić V; Kes P; Zeljko R; Kusec V
    Acta Med Croatica; 2006 Jun; 60(3):201-8. PubMed ID: 16933832
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Homocysteine as a predictive biomarker in early diagnosis of renal failure susceptibility and prognostic diagnosis for end stages renal disease.
    Amin HK; El-Sayed MI; Leheta OF
    Ren Fail; 2016 Sep; 38(8):1267-75. PubMed ID: 27435113
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Homocysteine-lowering therapy in renal disease.
    Austen SK; Coombes JS; Fassett RG
    Clin Nephrol; 2003 Dec; 60(6):375-85. PubMed ID: 14690253
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Mechanisms of homocysteine-induced glomerular injury and sclerosis.
    Yi F; Li PL
    Am J Nephrol; 2008; 28(2):254-64. PubMed ID: 17989498
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.